Methylergonovine
Methylergometrine, also known as methylergonovine and sold under the brand name Methergine, is a medication of the ergoline and lysergamide groups which is used as an oxytocic in obstetrics and as an antimigraine agent in the treatment of migraine headaches. It reportedly produces psychedelic effects similar to those of lysergic acid diethylamide (LSD) at high doses. Previously thought to be an exclusively synthetic compound, it has been reported to occur naturally in Argyreia nervosa. The drug is on the World Health Organization's List of Essential Medicines. — Wikipedia
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Earliest trial started Dec 28, 2017 (NCT03390010)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
HTR1B agonist
HTR1A agonist
HTR2A agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMethylergometrine ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05772156 | Phase 4 | Mar 7, 2023 | Columbia University |
| NCT03904446 | Phase 4 | Jul 1, 2019 | University of Iowa |
| NCT03303235 | Early Phase 1 (Phase 1) | Sep 30, 2018 | Johns Hopkins University |
| NCT03390010 | Phase 1 | Dec 28, 2017 | Aljazeera Hospital, Cairo University |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aljazeera Hospital | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Cairo University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Iowa | Academic/Hospital | 1 | 1 | 1 | 2019 |